Build a public biotechnology website that helps investors, partners, scientists, candidates and other stakeholders understand your company without flattening the science. Rudrriv structures scientific information, pipeline or program content, stakeholder paths, CMS workflows and technical delivery into one maintainable website.
Scientific, medical, legal and regulatory content remains subject to your organisation's qualified review and approval.
Explain the platform in plain language, then let technical audiences move into mechanism, evidence and program detail.
Biotech website pricing changes quickly once pipeline visualisation, scientific diagrams, content migration, multilingual publishing, investor relations or systems integration enter the brief. A focused public site can start at a defined entry point; broader builds are scoped after discovery.
For an early-stage or deliberately compact biotechnology organisation that needs a credible, maintainable public presence.
For teams with multiple programs, publications, investor/partner materials, news, careers or a significant existing content base.
For larger public websites or technical environments where the public site must connect with several external systems or complex publishing workflows.
Share the current site, target audiences, content readiness and any fixed launch date. We will separate public-site requirements from custom application or regulated-system work before quoting.
Biotechnology organisations often need one public website to support scientific credibility, corporate communication, fundraising or partnering, recruitment and ongoing updates. That changes the information architecture, review workflow and technical choices compared with a generic brochure site.
The strongest biotech sites do not force every visitor through the same corporate narrative. They let a general visitor understand the company quickly, while allowing technical stakeholders to move deeper into platform, pipeline, publications, posters or trial information when appropriate.
The public website should move a visitor from basic understanding to appropriate evidence and then into the correct next step—without treating every audience as a sales lead.
Search, referral, conference, publication, partner or investor introduction.
Company purpose, modality, technology or capability in clear language.
Pipeline, programs, publications, posters, news or approved supporting material.
Partnering, investor, careers, trial information or general corporate enquiry.
Deeper diligence, data rooms, applications or regulated workflows occur in the appropriate system.
The exact mix depends on your operating model: therapeutics, diagnostics, genomics, research tools, platform biotechnology, laboratories and other life-science organisations do not need identical site structures.
Explain what the organisation does, why the scientific approach matters and where deeper evidence sits.
Reusable structures for programs, stages, indications, targets or other approved fields.
Make publications, posters, presentations, press releases or news easier to find and maintain.
Keep contact paths aligned to visitor intent instead of relying on one generic conversion funnel.
This architecture prevents the homepage from becoming a dense scientific deck while still letting expert visitors verify the information they care about.
Pipeline content benefits from structured fields and publishing rules, especially when multiple teams need to update stage, indication, supporting material or program status over time.
Field labels, stage terminology, percentages and program status are illustrative only. The production component should use the organisation's approved taxonomy rather than generic assumptions.
Integration requirements are confirmed during discovery. The categories below are common possibilities, not claims of pre-approved partnership or universal compatibility.
Structured pages, reusable content types, editor roles and controlled update workflows.
Analytics, tag management or consent-aware measurement according to the agreed stack.
General enquiry routing, subscriber forms or careers integrations when there is a clear business need.
Approved links, feeds or a custom review of sources such as ClinicalTrials.gov when relevant.
A public biotechnology website is not a replacement for LIMS, ELN, CTMS, EDC, protected research infrastructure or authenticated data-room workflows. Those require separate technical and security scoping.
Clear inputs reduce delay, while clear deliverables prevent a design project from being mistaken for scientific, legal or regulatory validation.
The number of stages can expand for migrations, integrations or multi-stakeholder programmes, but the decision flow remains the same: define, structure, build, review, test and hand off.
Audience, goals, existing systems and launch constraints.
Output: scoped briefPages, scientific assets, approvals and migration needs.
Output: content mapNavigation, page types and stakeholder journeys.
Output: sitemap / flowsResponsive templates, diagrams and component design.
Output: approved layoutsCMS, front-end, content types and agreed integrations.
Output: working buildClient content approval plus technical validation and corrections.
Output: launch candidateDeployment, checks, CMS handoff and support route.
Output: live websiteBiotech quality checks need to cover both the technical build and the way scientific-adjacent content is governed before launch.
Headings, labels, references, downloads, pipeline fields and page relationships are reviewed for consistency with approved content.
Navigation, page components, forms, tables, diagrams and downloads are checked across representative viewport sizes and browsers.
Semantic markup, labels, focus states, keyboard access, contrast and responsive interaction are checked within the agreed scope.
Links, forms, analytics, redirects, metadata, feeds and other agreed integrations are tested before final handoff.
This is especially important when a marketing website sits near clinical, laboratory, investor, medical or research workflows.
If the primary requirement is a laboratory, clinical, transactional or authenticated operational application, a separate software scope may be more appropriate.
Teams that need a credible corporate presence for investors, partners, recruitment and public scientific communication before commercial launch.
Companies with evolving pipelines, trial-related public information, publications, investor materials and multiple internal approvers.
Organisations that need technical product/capability communication, evidence, application areas and appropriate commercial or partner routes.
Delivery time: confirmed after discovery. A fixed date is committed only after content, access, integration and approval dependencies are understood.
These answers define the service boundary, commercial model, technical expectations and the review responsibilities that matter most before work starts.
A focused project can include information architecture, responsive UI design, front-end and CMS development, company and platform pages, pipeline or program content structures, publications or news areas, general enquiry paths, technical SEO foundations, QA and launch handoff. Integrations, migrations, multilingual content, investor-relations feeds or custom applications are scoped separately when needed.
Biotechnology websites often have to serve scientific, investor, partner, recruitment and sometimes patient or clinical-trial audiences at the same time. The site therefore needs clear audience routes, evidence-led scientific content, careful claim presentation, maintainable pipeline or program information and a review workflow that respects the organisation's scientific and regulatory approvals.
Yes. Pipeline and program content can be structured into reusable website components so visitors can scan indications, targets, modalities, stages and supporting material when those fields are appropriate and supplied by your team. Rudrriv does not independently validate scientific claims or regulatory status; content should be approved by the responsible client stakeholders before publication.
Yes, a public website can link to or present client-approved clinical-trial information. Where appropriate, a separate custom scope can evaluate a ClinicalTrials.gov data connection or other approved data source. The website should not be treated as a clinical-trial management system or a substitute for official trial records.
No. Rudrriv provides website design and development support, not legal, medical, regulatory or certification services. We can build structures that support your approved disclaimers, review checkpoints, accessibility requirements and content governance, while your qualified stakeholders remain responsible for the scientific, legal and regulatory approval of published content.
Yes. Early-stage teams often need a focused website that explains the company, platform, lead programs, leadership, news, careers and contact routes without overbuilding. The final scope depends on the amount of approved content, branding readiness, investor or partnering needs and how quickly the site must evolve.
A redesign can include a content inventory, URL mapping, redirect planning, metadata migration and technical QA so existing search equity is considered during the move. The exact migration plan depends on the current CMS, URL structure, content volume and access available.
Depending on the project, possible dependencies can include a CMS, CRM, email marketing platform, analytics, consent management, ATS or careers platform, investor-relations/news feeds, document libraries and approved scientific data sources. Named integrations are confirmed during discovery rather than assumed in advance.
The build includes responsive layouts and accessibility-conscious implementation such as semantic HTML, keyboard-friendly controls, visible focus states, readable contrast and form labels. If your organisation requires formal WCAG conformance evidence or an external accessibility audit, that should be included as a defined project requirement or separate specialist review.
A focused biotech marketing website can start from $3,500 for a deliberately limited scope. Larger builds are quoted after discovery because pipeline complexity, custom visualisation, content migration, integrations, multilingual requirements, stakeholder review and regulated-content workflows can change the work substantially.
The delivery schedule is confirmed after scope review. Timing depends on content and brand readiness, number of page types, scientific diagrams or interactive elements, stakeholder approvals, migration volume, integrations and review cycles. Fixed launch dates should be raised during the initial enquiry so feasibility can be assessed before commitment.
Useful inputs include the website objective, priority audiences, approved brand assets, existing site or CMS access, page and content inventory, platform and pipeline information, publications or news requirements, integration details, analytics access, legal or regulatory content instructions, approval owners and any fixed launch date.
Website copy structuring and content refinement can be scoped, but scientific facts, study claims, product status, mechanism descriptions and regulatory statements must be supplied or approved by the client. Independent scientific verification, medical writing, legal review and regulatory review are not automatically included in website development.
Handoff can include deployment support, CMS access, reusable page components, basic editing guidance and a defined correction period for implementation defects. Ongoing maintenance, content updates, security upkeep, new program pages, analytics work or feature development can be scoped separately.
A separate application scope is usually more appropriate when you need authenticated portals, protected research data, laboratory workflows, LIMS or ELN functionality, clinical-trial management, complex account permissions, transactional systems or deep operational integrations. The public biotech website should not be stretched into systems it was not designed to replace.
Email ID, Phone and Requirement Details are required. Name is optional.
